Using multicriteria decision analysis during drug development to predict reimbursement decisions

Journal of Market Access and Health Policy

Volumn 2, Issue 1, 2014, Pages

  Williams, Paul ^a   Mauskopf, Josephine ^a   Lebiecki, Jake ^a   Kilburg, Anne ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

additional benefit; cost effectiveness; Germany; multicriteria decision analysis; reimbursement; Spain; United Kingdom

Indexed keywords

EID: 84995635201     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v2.25270     Document Type: Article

References (17)

1. ThokalaP.Multiple criteria decision analysis for health technology assessment. Report by the Decision Support Unit. 2011; Sheffield, UK: University of Sheffield.
2. WalkerS, PhillipsL, ConeM.Benefit risk assessment model for medicines: Developing a structured approach to decision making. 2006; Epsom: Center for Medicines Research International, Institute for Regulatory Science.
3. MussenF, SalekS, WalkerS.A quantitative approach to benefit-risk assessment of medicines–Part 1: The development of a new model using multi-criteria decision analysis. Pharmacoepidemiol Drug Saf. 2007; 16: S2–S15. [PubMed Abstract].
4. SussexJ, TowseA, DevlinN.Operationalizing value-based pricing of medicines: A taxonomy of approaches. Pharmacoeconomics. 2013; 31: 1–10. [PubMed Abstract].
5. GioveS, RosatoP, BreilM.An application of multicriteria decision making to built heritage. The redevelopment of Venice Arsenale. J Multi Criteria Decis Anal. 2010; 17: 85–99.
6. LinkovI, StevensJ. HudnellHK. Multi-criteria decision analysis (Chapter 35, Appendix A). Cyanobacterial harmful algal blooms: State of the science and research needs. 2008; New York: Springer Science+Business Media, LLC.815–29. Advances in experimental medicine and biology. Vol. 619.
7. TonyMM, WagnerM, KhouryH, RindressD, PapastravosT, OhP et al. Bridging health technology assessment (HTA) with multicriteria decision analysis (MCDA): Field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011; 11: 329. [PubMed Abstract] [PubMed CentralFull Text].
8. Department for Communities and Local Government.Multi-criteria analysis: A manual. 2009. Available from: http://eprints.lse.ac.uk/12761/1/Multi-criteria_Analysis.pdf [cited 12 June 2014].
9. ThokalaP, DuenasA.Multiple criteria decision analysis for health technology assessment. Value Health. 2012; 15: 1172–81. [PubMed Abstract].
10. RotterJS, FoersterD, BridgesJF.The changing role of economic evaluation in valuing medical technologies. Expert Rev Pharmacoecon Outcomes Res. 2012; 12: 711–23. [PubMed Abstract].
11. PoulinP, AustenL, ScottCM, WaddellCD, DixonE, PoulinM et al. Multi-criteria development and incorporation into decision tools for health technology adoption. J Health Organ Manag. 2013; 27: 246–65. [PubMed Abstract].
12. DodgsonJS, SpackmanM, PearmanA, PhillipsLD.Multi-criteria analysis: A manual. 2009; London: Department for Communities and Local Government.
13. AntoñanzasF, OliviaJ, PinillosM, JuarezC.Economic aspects of the new Spanish law on pharmaceutical preparations. Eur J Health Econ. 2007; 8: 297–300.
14. GarattiniL, CornagoD, De CompadriP.Pricing and reimbursement of in-patient drugs in seven European countries: A comparative analysis. Health Policy. 2007; 82: 330–9. [PubMed Abstract].
15. DevlinN, ParkinD.Does NICE have a cost-effectiveness threshold and what other factors influence its decisions?. A binary choice analysis. Health Econ. 2004; 13: 437–52.
16. HarrisAH, HillSR, ChinG, LiJJ, WalkomE.The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994–2004. Med Decis Making. 2008; 28: 713–22. [PubMed Abstract].
17. PezzulloJC, SullivanKM.Logistic regression. Available from: http://statpages.org/logistic.html [cited 6 September 2014].